|Bid||4.4820 x N/A|
|Ask||4.4900 x N/A|
|Day's Range||4.4800 - 4.4960|
|52 Week Range||3.8000 - 5.0990|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / November 27, 2020 / Nanoform Finland Plc (STO:NANOFH) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 27, 2020 at 3:00 PM Eastern Time.
Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, one more non-GMP line commissioned and a new near-term business target introduced: "First Biologics PoC project in 2021".
Nanoform's half year financial report January-June 2020: Positive momentum continues to build after successful IPO, near-term business target: "to acquire more new customers in 2020 than in 2019" achieved in July.